Upregulation of Trefoil Factor 3 (TFF3) After Rectal Cancer Chemoradiotherapy Is an Adverse Prognostic Factor and a Potential Therapeutic Target
Enrique Casado(Hospital Universitario Infanta Sofía), Paloma Cejas(Dana-Farber Cancer Institute), Juan Moreno‐Rubio(Hospital La Paz Institute for Health Research), Víctor Moreno, Pilar Díez Vázquez(Hospital Universitario La Paz), Miriam López-Gómez(Hospital Universitario Infanta Sofía), Cristóbal Belda-Iniesta(Instituto de Salud Carlos III), Joan Maurel(Breast Cancer Research Foundation), María Sereno(Hospital Universitario Infanta Sofía), César Gómez-Raposo(Hospital Universitario Infanta Sofía), Juan Carlos Lacal(Consejo Superior de Investigaciones Científicas), Carlos Fernández-Martos(Fundación Instituto Valenciano de Oncología), Francisco Zambrana(Hospital Universitario Infanta Sofía), Miguel Ángel García‐Cabezas(Boston University), Rocío López(Cleveland Clinic), Beatriz Castelo, Manuel González-Barón(Hospital Universitario La Paz), José Javier Sánchez(Research Institute Hospital 12 de Octubre), Jaime Feliú(Hospital Universitario La Paz), Emilio Burgos(Hospital Universitario Infanta Sofía), María Teresa Gómez del Pulgar(Consejo Superior de Investigaciones Científicas)
International Journal of Radiation Oncology*Biology*Physics
April 19, 2012
Cited by 23
Related Papers
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|The Lancet Oncology|2018|579
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
|The Lancet Oncology|2019|564
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
|Cancer Discovery|2021|286